Amiodarone & Radiotherapy — Risk Mitigation Guide ● Radiation Oncology · Cardio-Oncology Interface Amiodarone & Radiotherapy:Risk Mitigation Across Sites A practical, site-by-site guide for radiation oncologists, cardiologists, and MDT teams managing patients on amiodarone who require radiotherapy — from thoracic EBRT to radioiodine therapy. 6 RT settings covered APT Key mechanism MDT Always required 20+…
Prostate Cancer · Localised Disease Cambridge Prognostic GroupsCPG 1–5 at a glance A fast-reference guide for busy clinicians — risk stratification, staging patterns, and treatment intent for localised prostate cancer CPG 1 — Low risk CPG 2 — Intermediate favourable CPG 3 — Intermediate unfavourable CPG 4 — High risk CPG 5 — Very high…
Clinical Pharmacology · Oncology & Cardiology Interface
Oncology Clinical Update · Hepatocellular Carcinoma
The “In a Nutshell” Intro While definitive chemoradiotherapy (dCRT) is the gold standard for non-surgical esophageal cancer, systemic relapse remains a formidable foe for over 50% of patients. This post explores whether “bioselection” via induction chemotherapy (IC) can actually move the needle on survival or if it’s just delaying the inevitable.
MATTERHORN & SPOTLIGHT: Precision Medicine Redefining the Gastric Cancer Paradigm In a nutshell: The “one-size-fits-all” FLOT era is evolving. With the MATTERHORN trial maturing and zolbetuximab entering the UK market, we are witnessing a shift toward biomarker-driven strategies in both the perioperative and metastatic settings.
The New Dawn in Bladder Cancer: EV-302 and the End of the “Chemo-Only” Era In a Nutshell: The standard of care for advanced urothelial cancer has remained stagnant for decades—until now. The combination of Enfortumab Vedotin and Pembrolizumab is nearly doubling survival rates, fundamentally rewriting the NHS treatment pathway.
ESMO Oncology Weekly Digest — 8–15 February 2026 Key Takeaways • ESMO Oesophageal CPG Interim Update confirms perioperative FLOT as the preferred standard over neoadjuvant chemoradiotherapy (CROSS) for locally advanced oesophageal/OGJ adenocarcinoma, based on the phase III ESOPEC trial (mOS 66 vs 37 months; HR 0.70). Tislelizumab–ChT added for first-line advanced oesophageal SCC.[1][2] • …
Weekly Oncology Literature Round-Up 8–15 February 2026 | Key Journals Scan